Tengion completes initial 6M common stock public offering

Apr 15 2010NewsGuard 100/100 Score

Tengion, Inc. (Nasdaq: TNGN), a regenerative medicine company focused on discovering, developing, manufacturing and commercializing neo-organs and neo-tissues, today announced the completion of its initial public offering of 6,000,000 shares of common stock at a price of $5.00 per share.  The net proceeds of the offering to Tengion, after deducting underwriting discounts and commissions and estimated offering expenses payable by Tengion, were approximately $26.0 million. In addition, Tengion has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares to cover over-allotments, if any.  The joint book-running managers of the offering are Piper Jaffray & Co. and Leerink Swann LLC.

Source:

Tengion, Inc.

Posted in:

Tags: , , , , , , ,

Comments (0)

Suggested Reading

Cellular Origins, Fresenius Kabi sign development agreement for scalable automation of cell and gene therapy manufacturing
Sapio Sciences introduces Sapio GMP LIMS offering unmatched flexibility for unique manufacturing processes
Study shows large language models susceptible to misinformation
Step up your cosmetics manufacturing with OHAUS!
How Aloe vera's medicinal properties make it essential in medicine, cosmetics, and food products
Cellular Origins acquires Actia Platform IP to enhance automated cell therapy manufacturing
Living well is the best medicine: Study links healthy habits to lower mortality in hypertensive individuals
AHN Biotechnologie GmbH – Premium private label manufacturing biotechnology

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Revolutionising organoid manufacturing: Monmouth Scientific Class 2 Biological Safety Cabinets enhance sterility and efficiency at Molecular Devices' new Life Science facility.